Jazz Operating Income from 2010 to 2025

JAZZ Stock

USD 135.25 6.77 4.77%

Jazz Pharmaceuticals Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Jazz Pharmaceuticals PLC generates from its operations. View All Fundamentals

Operating Income

First Reported

2005-03-31

Previous Quarter

260.2 M

Current Value

190.8 M

Quarterly Volatility

88.5 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 250 M, Other Operating Expenses of 3.5 B or Operating Income of 752.5 M, as well as many indicators such as Price To Sales Ratio of 1.78, Dividend Yield of 0.0 or PTB Ratio of 1.77. Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.

Latest Jazz Pharmaceuticals' Operating Income Growth Pattern

Below is the plot of the Operating Income of Jazz Pharmaceuticals PLC over the last few years. Operating Income is the amount of profit realized from Jazz Pharmaceuticals PLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Jazz Pharmaceuticals PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Jazz Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jazz Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Jazz Operating Income Regression Statistics

	Arithmetic Mean	444,273,594
	Coefficient Of Variation	54.93
	Mean Deviation	207,324,195
	Median	528,842,000
	Standard Deviation	244,052,037
	Sample Variance	59561.4T
	Range	790.3M
	R-Value	0.75
	Mean Square Error	28130.4T
	R-Squared	0.56
	Significance	0.0009
	Slope	38,332,754
	Total Sum of Squares	893420.9T

Jazz Operating Income History

	2025	752.5 M
	2024	716.6 M
	2023	578.6 M
	2022	512.3 M
	2021	170.3 M
	2020	765.5 M
	2019	532.4 M

Other Fundumenentals of Jazz Pharmaceuticals PLC

Non Operating Income Net Other

Jazz Pharmaceuticals Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.92	0.31	0.8	0.95	0.98	0.98	0.99	0.34	0.99	0.91	0.96	0.95	0.67	0.4	0.0	-0.9	0.91	0.7	0.97	-0.43	0.92	0.7	0.8	-0.53
Total Stockholder Equity	0.92		0.23	0.94	0.82	0.83	0.91	0.92	0.59	0.84	0.88	0.85	0.92	0.59	0.41	0.15	-0.68	0.89	0.57	0.81	-0.51	0.75	0.77	0.77	-0.47
Net Debt	0.31	0.23		0.15	0.46	0.28	0.24	0.36	-0.31	0.33	-0.04	0.52	0.28	-0.32	0.36	0.59	-0.43	0.43	-0.09	0.24	-0.05	0.34	0.17	-0.04	0.56
Retained Earnings	0.8	0.94	0.15		0.66	0.68	0.79	0.8	0.7	0.69	0.77	0.72	0.85	0.5	0.34	0.14	-0.51	0.79	0.49	0.66	-0.58	0.56	0.76	0.69	-0.42
Accounts Payable	0.95	0.82	0.46	0.66		0.95	0.94	0.95	0.14	0.96	0.81	0.95	0.92	0.61	0.45	0.05	-0.92	0.88	0.63	0.94	-0.29	0.93	0.68	0.7	-0.39
Long Term Debt	0.98	0.83	0.28	0.68	0.95		0.96	0.96	0.22	1.0	0.89	0.94	0.91	0.69	0.33	-0.12	-0.94	0.86	0.74	1.0	-0.4	0.94	0.63	0.78	-0.57
Net Receivables	0.98	0.91	0.24	0.79	0.94	0.96		0.97	0.39	0.97	0.95	0.9	0.94	0.74	0.46	-0.06	-0.85	0.9	0.76	0.96	-0.38	0.9	0.71	0.83	-0.57
Good Will	0.99	0.92	0.36	0.8	0.95	0.96	0.97		0.29	0.97	0.88	0.97	0.95	0.63	0.4	0.11	-0.9	0.92	0.71	0.95	-0.48	0.88	0.68	0.74	-0.48
Short Term Investments	0.34	0.59	-0.31	0.7	0.14	0.22	0.39	0.29		0.22	0.55	0.16	0.37	0.36	0.22	-0.14	0.06	0.35	0.19	0.23	-0.27	0.17	0.63	0.58	-0.42
Total Liab	0.99	0.84	0.33	0.69	0.96	1.0	0.97	0.97	0.22		0.88	0.96	0.92	0.68	0.38	-0.07	-0.95	0.88	0.73	0.99	-0.38	0.95	0.64	0.77	-0.53
Total Current Assets	0.91	0.88	-0.04	0.77	0.81	0.89	0.95	0.88	0.55	0.88		0.76	0.85	0.83	0.42	-0.21	-0.71	0.8	0.75	0.9	-0.33	0.84	0.68	0.89	-0.72
Intangible Assets	0.96	0.85	0.52	0.72	0.95	0.94	0.9	0.97	0.16	0.96	0.76		0.92	0.5	0.34	0.13	-0.94	0.89	0.6	0.92	-0.45	0.88	0.63	0.65	-0.35
Property Plant Equipment	0.95	0.92	0.28	0.85	0.92	0.91	0.94	0.95	0.37	0.92	0.85	0.92		0.63	0.31	-0.02	-0.83	0.88	0.62	0.91	-0.53	0.83	0.78	0.74	-0.51
Current Deferred Revenue	0.67	0.59	-0.32	0.5	0.61	0.69	0.74	0.63	0.36	0.68	0.83	0.5	0.63		0.46	-0.47	-0.59	0.5	0.8	0.74	-0.03	0.65	0.45	0.71	-0.79
Short Term Debt	0.4	0.41	0.36	0.34	0.45	0.33	0.46	0.4	0.22	0.38	0.42	0.34	0.31	0.46		0.17	-0.31	0.43	0.34	0.36	0.36	0.43	0.29	0.35	0.03
Common Stock	0.0	0.15	0.59	0.14	0.05	-0.12	-0.06	0.11	-0.14	-0.07	-0.21	0.13	-0.02	-0.47	0.17		0.05	0.18	-0.2	-0.18	-0.21	-0.16	-0.01	-0.28	0.6
Net Tangible Assets	-0.9	-0.68	-0.43	-0.51	-0.92	-0.94	-0.85	-0.9	0.06	-0.95	-0.71	-0.94	-0.83	-0.59	-0.31	0.05		-0.79	-0.7	-0.94	0.32	-0.9	-0.49	-0.6	0.4
Capital Surpluse	0.91	0.89	0.43	0.79	0.88	0.86	0.9	0.92	0.35	0.88	0.8	0.89	0.88	0.5	0.43	0.18	-0.79		0.57	0.84	-0.42	0.88	0.71	0.83	-0.23
Deferred Long Term Liab	0.7	0.57	-0.09	0.49	0.63	0.74	0.76	0.71	0.19	0.73	0.75	0.6	0.62	0.8	0.34	-0.2	-0.7	0.57		0.76	-0.28	0.62	0.39	0.58	-0.65
Long Term Debt Total	0.97	0.81	0.24	0.66	0.94	1.0	0.96	0.95	0.23	0.99	0.9	0.92	0.91	0.74	0.36	-0.18	-0.94	0.84	0.76		-0.35	0.95	0.62	0.79	-0.6
Short Long Term Debt	-0.43	-0.51	-0.05	-0.58	-0.29	-0.4	-0.38	-0.48	-0.27	-0.38	-0.33	-0.45	-0.53	-0.03	0.36	-0.21	0.32	-0.42	-0.28	-0.35		-0.17	-0.37	-0.23	0.26
Net Invested Capital	0.92	0.75	0.34	0.56	0.93	0.94	0.9	0.88	0.17	0.95	0.84	0.88	0.83	0.65	0.43	-0.16	-0.9	0.88	0.62	0.95	-0.17		0.59	0.84	-0.42
Long Term Investments	0.7	0.77	0.17	0.76	0.68	0.63	0.71	0.68	0.63	0.64	0.68	0.63	0.78	0.45	0.29	-0.01	-0.49	0.71	0.39	0.62	-0.37	0.59		0.66	-0.35
Net Working Capital	0.8	0.77	-0.04	0.69	0.7	0.78	0.83	0.74	0.58	0.77	0.89	0.65	0.74	0.71	0.35	-0.28	-0.6	0.83	0.58	0.79	-0.23	0.84	0.66		-0.52
Capital Stock	-0.53	-0.47	0.56	-0.42	-0.39	-0.57	-0.57	-0.48	-0.42	-0.53	-0.72	-0.35	-0.51	-0.79	0.03	0.6	0.4	-0.23	-0.65	-0.6	0.26	-0.42	-0.35	-0.52

Click cells to compare fundamentals

About Jazz Pharmaceuticals Financial Statements

Jazz Pharmaceuticals investors use historical fundamental indicators, such as Jazz Pharmaceuticals' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jazz Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	716.6 M	752.5 M
Non Operating Income Net Other	-26 M	-24.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jazz Operating Income from 2010 to 2025

Latest Jazz Pharmaceuticals' Operating Income Growth Pattern

Jazz Operating Income Regression Statistics

Jazz Operating Income History

Other Fundumenentals of Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals Operating Income component correlations

About Jazz Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for Jazz Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY